Navigation Links
INNOPHARMA Receives First FDA Approval
Date:2/2/2010

MONMOUTH JUNCTION, N.J., Feb. 2 /PRNewswire/ -- INNOPHARMA LLC announced today FDA approval of the Abbreviated New Drug Application (ANDA) for ibutilide fumarate injection (the generic equivalent of Corvert® from Pfizer Inc).

As the developer of this generic injectable drug, INNOPHARMA entered into a license agreement with Bioniche Pharma USA for marketing and product distribution of the injection product. Ibutilide fumarate injection represents INNOPHARMA's first approved drug in their product pipeline.

Please refer to the Bioniche Pharma website to be directed to the complete prescribing information for this product, including the boxed warning.

About INNOPHARMA:

INNOPHARMA is a research and development company, focused on developing niche generic and specialty pharmaceutical products.  Through a business model of internal product development and commercialization licensure, INNOPHARMA has a comprehensive infrastructure for development of parenteral pharmaceutical products at its New Jersey facilities.  INNOPHARMA works with manufacturing and clinical research organizations worldwide for commercialization of its developed products.  More information about INNOPHARMA can be found at www.innopharmallc.com.  

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, including anesthesiology, orthopedics, rheumatology, urology, and dermatology. An internal development pipeline and an aggressive acquisition strategy for products fuel the company's growth. RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois, acquired Bioniche Pharma in February 2006. More information about Bioniche Pharma can be found at www.bionichepharma.com.

SOURCE INNOPHARMA LLC

RELATED LINKS
http://www.innopharmallc.com

'/>"/>

SOURCE INNOPHARMA LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
2. Mylan Receives Approval for Generic Version of GoLytely(R)
3. Merck Receives European Approval for ELONVA(R) (corifollitropin alfa injection), a New Fertility Treatment
4. Notal Visions ForeseeHome(TM) AMD Monitor Receives FDA Clearance
5. Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance
6. Novo Nordisks Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
7. KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes to Approve Appointment of Director
8. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
9. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
10. GeneGo Receives SBIR Grant
11. WorldHeart Receives Unconditional BTT Study Approval From FDA for Levacor(TM) VAD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Actinic Keratosis Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Actinic Keratosis epidemiology, Actinic Keratosis market valuations ...
(Date:5/3/2016)... Research and Markets has announced the addition ... Outlook 2020" report to their offering. ... has improved significantly in past years due to which ... years. Many cancer drugs have been developed by utilization ... expected to be developed with its help. They are ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK , ... today announced Food and Drug Administration (FDA) approval ... that provides heart failure patients with access to ... also have remote monitoring with daily automatic transmission ... heart rate in response to physiological demands. ...
Breaking Medicine Technology:
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... among Pittsburgh-area schoolchildren has found that more than 40 percent of participating fifth-grade ... MD , Director of Allergy and Asthma Clinical Research in the Division of ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... Dr. Benjamin ... in non-surgical hair loss treatment. Dr. Stong is double board certified and the ... for the treatment of hair loss. Non-surgical therapies such as stem cells can ...
(Date:5/5/2016)... ... May 05, 2016 , ... The 2016 Nike Soccer Camp will be directed ... university coaching staff. Together they bring their winning Vandals coaching philosophy to young athletes. ... ages 5-13, and high school players. Session dates are as follows: , Youth Day ...
(Date:5/5/2016)... ... May 05, 2016 , ... When stiff and achy joints ... the pain that’s a common osteoarthritis (OA) symptom. Yet, numerous clinical studies point ... arthritis. , “Physical therapy exercises are commonly prescribed to individuals with osteoarthritis ...
(Date:5/5/2016)... ... ... Lung Institute will celebrate its three-year anniversary on May 14 by giving away ... month of May. To date, the Lung Institute has treated over 2,000 people at their ... testament to the success of this treatment and to the patients who refuse to give ...
Breaking Medicine News(10 mins):